The primary objective of this proposal is to improve the therapeutic outcome for adults with primary brain tumors. The secondary objective is to share clinical and laboratory data and human brain tumor specimens to conduct research pertaining to the basic biology of primary brain tumors, the neuro-pharmacology of novel therapies, and improving the care and quality of life of adults with primary brain tumors. These objectives will be accomplished by conducting Phase I and II clinical trials using promising new agents, biologic approaches, routes of administration, and trial designs for the treatment of primary brain tumors through the continued efforts of the """"""""New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium."""""""" This consortium combines and focuses the experience, resources, and capabilities of ten outstanding medical institutions (Cleveland Clinic, Emory University, Henry Ford Hospital, Johns Hopkins University, Massachusetts General Hospital, Moffitt Cancer Center, National Cancer Institute Intramural Neuro-Oncology Program, the University of Alabama at Birmingham, University of Pennsylvania, and Wake Forest University) to bear on primary brain tumors. These participating institutions have (1) a large number of adults with primary brain tumors, (2) expert multidisciplinary clinical teams caring for these patients, (3) extensive clinical, laboratory, and imaging resources, (4) many high quality, clinically relevant, peer-reviewed, clinical and laboratory brain tumor research projects, (5) nationally recognized expertise in oncology, pharmacology, new drug development, clinical trials, neurosurgery, and neuropathology (6) extensive expertise in biostatistics, data management, and the coordination of multi-institutional studies, and (7) exceptional reputations for excellence in clinical care and research. The consortium adds to these institutional strengths with: (1) a formal, comprehensive organizational structure, (2) a stable and smoothly functioning Central Operations Office, (3) outstanding biostatistics, pharmacology, and correlative biology, (4) an emphasis on trial design, protocol development, quality control, study monitoring, and data analysis, and (5) collaborations with pharmaceutical companies, a computing consortium, and other scientists conducting brain tumor research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA062475-12
Application #
7127606
Study Section
Special Emphasis Panel (ZCA1-SRRB-E (O2))
Program Officer
Wu, Roy S
Project Start
2004-05-17
Project End
2008-12-31
Budget Start
2006-08-25
Budget End
2006-12-31
Support Year
12
Fiscal Year
2006
Total Cost
$510,290
Indirect Cost
Name
Johns Hopkins University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Blakeley, Jaishri O; Grossman, Stuart A; Chi, Andrew S et al. (2018) Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma. Clin Cancer Res :
Blakeley, Jaishri O; Grossman, Stuart A; Mikkelsen, Tom et al. (2015) Phase I study of iniparib concurrent with monthly or continuous temozolomide dosing schedules in patients with newly diagnosed malignant gliomas. J Neurooncol 125:123-31
Rosenfeld, Myrna R; Ye, Xiaobu; Supko, Jeffrey G et al. (2014) A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. Autophagy 10:1359-68
Peereboom, David M; Ahluwalia, Manmeet S; Ye, Xiaobu et al. (2013) NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme. Neuro Oncol 15:490-6
Grossman, Stuart A; Ye, Xiaobu; Peereboom, David et al. (2012) Phase I study of terameprocol in patients with recurrent high-grade glioma. Neuro Oncol 14:511-7
Nabors, L Burt; Mikkelsen, Thomas; Hegi, Monika E et al. (2012) A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306). Cancer 118:5601-7
Rudek, Michelle A; New, Pamela; Mikkelsen, Tom et al. (2011) Phase I and pharmacokinetic study of COL-3 in patients with recurrent high-grade gliomas. J Neurooncol 105:375-81
Batchelor, T T; Grossman, S A; Mikkelsen, T et al. (2011) Rituximab monotherapy for patients with recurrent primary CNS lymphoma. Neurology 76:929-30
Nabors, L B; Supko, J G; Rosenfeld, M et al. (2011) Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma. Neuro Oncol 13:1324-30
Grossman, Stuart A; Ye, Xiaobu; Lesser, Glenn et al. (2011) Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clin Cancer Res 17:5473-80

Showing the most recent 10 out of 42 publications